Each common unit consists of one common share and one warrant. Each warrant will expire five years from date of issuance. ThinkEquity is the underwriter for this offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Therapeutics: Promising Phase 3 Trial Progress and Strategic Financial Management Justify Buy Rating
- BriaCell Advances Phase 3 Study in Metastatic Breast Cancer
- BriaCell announces ongoing Phase 3 study enrolled over 75 patients
- BriaCell’s Phase 2 Study Shows Promising Survival Data in Breast Cancer
- BriaCell announces survival data from its Phase 2 study of Bria-IMT